Tag: False Claims Act

Posted on

Healthcare Fraud Whistleblower Rewards: Your Complete Legal Guide

Equal Pay and Anti-Retaliation Protection Act protects from retaliation.

Healthcare Fraud Whistleblowing: Your Path to Justice and Reward

Healthcare fraud costs taxpayers billions each year, but brave insiders are fighting back—and getting rewarded for it. The recent Capstone Diagnostics case demonstrates how one whistleblower’s courage led to a $14.3 million settlement and a personal reward of $2.86 million.

Healthcare fraud schemes drain resources from vital programs like Medicare and Medicaid while putting vulnerable patients at risk. These illegal operations often rely on kickbacks, false claims, and manipulated billing to maximize profits at taxpayers’ expense. Without whistleblowers stepping forward, many of these fraudulent schemes would continue unchecked.

Understanding your rights and potential rewards as a healthcare fraud whistleblower can help you make an informed decision about reporting illegal activities. The legal framework protecting whistleblowers has grown stronger over the years, offering substantial financial incentives alongside robust anti-retaliation protections.

The Anti-Kickback Statute and Its Critical Role

The Anti-Kickback Statute (AKS) serves as a cornerstone of healthcare fraud prevention. This federal law prohibits offering, paying, soliciting, or receiving anything of value in exchange for referrals of patients covered by federal healthcare programs like Medicare and Medicaid.

Healthcare providers violate the AKS when they accept meals, money, free rent, or other valuable items in exchange for patient referrals. These kickback arrangements corrupt medical decision-making, leading to unnecessary tests and procedures that burden federal programs with excessive costs.

Principal Deputy Assistant Attorney General Brian M. Boynton emphasized the statute’s importance: “The law prohibits healthcare providers, including laboratories, from paying kickbacks to third parties to generate business.” These corrupt practices severely damage the integrity of healthcare programs designed to serve our most vulnerable populations.

Violations of the AKS automatically trigger False Claims Act liability, meaning that every claim submitted downstream from an illegal kickback arrangement becomes a potential source of significant financial penalties.

Capstone Diagnostics: A Case Study in Healthcare Fraud

The Capstone Diagnostics case illustrates how kickback schemes operate and the substantial rewards available to whistleblowers. A.M., the 57-year-old owner of this Georgia clinical laboratory, admitted to felony conspiracy charges and agreed to pay over $14 million to settle allegations of illegal kickback payments.

Capstone targeted vulnerable federal healthcare programs and Georgia Medicaid by paying commissions to generate unnecessary medical tests, including urine drug tests and respiratory pathogen panels. The scheme involved paying portions of Medicaid reimbursements to operators of an after-school program in exchange for urine specimen drug testing samples.

The fraudulent operation submitted $1 million in claims related to fake drug testing, with Georgia Medicaid covering at least $400,000 of those claims. During the COVID-19 pandemic, A.M.’s laboratory exploited the crisis by forging signatures to order tests and manipulating demand for respiratory tests in senior communities.

The whistleblower in this case received approximately $2.86 million as a reward for providing crucial information that led to the successful prosecution. This substantial payout demonstrates the financial incentives available to those who courageously report healthcare fraud.

Understanding the False Claims Act Framework

The False Claims Act (FCA), originally enacted during the Civil War to combat defense contractor fraud, has evolved into the government’s primary tool for fighting healthcare fraud. This powerful statute enables private citizens, known as relators, to file qui tam lawsuits on behalf of the government against entities that have defrauded federal programs.

Successful whistleblowers can receive between 15% and 30% of the total recovery, depending on whether the government intervenes in the case. In cases where the government chooses not to intervene, rewards can reach up to 30% of the recovery amount. For example, if a relator helps recover $100 million in a lawsuit, they could potentially receive up to $30 million as a whistleblower rewards.

The FCA covers various fraudulent activities, including:

  • Knowingly presenting false claims for payment to the federal government
  • Using false records or statements to secure government payments
  • Conspiring to submit fraudulent claims
  • Concealing obligations to pay money to the government

Since billing completed downstream of kickback arrangements may be considered illegitimate, all related public billing costs could potentially constitute FCA violations. This multiplier effect significantly increases the potential recovery amounts in healthcare fraud cases.

COVID-19 Fraud Enforcement and Enhanced Protections

The COVID-19 pandemic created unprecedented opportunities for healthcare fraud as billions of dollars in emergency funding became available. Recognizing this threat, the Department of Justice established the COVID-19 Fraud Enforcement Task Force on May 17, 2021, to investigate and prosecute criminal and civil fraud against pandemic relief programs.

Healthcare providers exploited the pandemic’s urgency and confusion to submit fraudulent claims for COVID-19 testing, treatments, and other services. The Capstone case exemplifies this trend, with the laboratory forging signatures and manipulating testing demand to profit from pandemic-related programs.

The DOJ actively seeks whistleblowers who can provide actionable information about COVID-19 fraud schemes. These cases often involve substantial financial recoveries due to the large amounts of federal funding involved, making them particularly attractive for potential whistleblowers seeking anti-corruption enforcement.

Healthcare workers, laboratory technicians, billing specialists, and other industry insiders who witnessed fraudulent activities during the pandemic may have valuable information that could lead to significant whistleblower rewards.

Maximizing Your Chances of Whistleblower Success

Successfully pursuing a healthcare fraud whistleblower case requires careful preparation and experienced legal representation. Several factors can significantly impact your chances of success and the size of your potential reward.

Building a Strong Foundation

Document everything you can safely obtain that supports your allegations of fraud. This includes billing records, emails, memos, contracts, and any other evidence of kickback arrangements or false claims. The strength of your evidence directly correlates to your case’s success potential.

Understand the scope of the fraud you’re reporting. Cases involving larger financial amounts typically result in higher whistleblower rewards. Federal prosecutors prioritize cases with significant financial impact and clear evidence of intentional wrongdoing.

Avoiding Retaliation Risks

The False Claims Act provides robust protection against retaliation for employees who report healthcare fraud. Under Section 3730(h), employers cannot discharge, demote, harass, or discriminate against employees who engage in protected whistleblowing activities.

If you experience wrongful termination or other retaliation, you may be entitled to reinstatement, double back pay, and compensation for special damages, including litigation costs and attorney fees. These protections help ensure that doing the right thing doesn’t cost you your livelihood.

Working with Experienced Counsel

Healthcare fraud cases involve complex legal and regulatory issues that require specialized expertise. Experienced anti-kickback whistleblower attorneys understand how to assess case strengths, navigate the qui tam process, and maximize potential rewards while protecting clients from retaliation.

Your attorney will help you file the case under seal, prepare the required disclosure statement, and work with federal prosecutors to investigate your allegations. This collaborative approach significantly increases your chances of a successful outcome.

Taking Action Against Healthcare Fraud

Healthcare fraud undermines the integrity of programs designed to serve our most vulnerable citizens while wasting billions in taxpayer dollars. Whistleblowers play a crucial role in exposing these schemes and holding wrongdoers accountable.

The substantial rewards available under the False Claims Act—potentially millions of dollars for successful cases—provide strong financial incentives for reporting fraud. Combined with robust anti-retaliation protections, these laws create a framework that encourages and protects those who choose to speak out against corruption.

If you have knowledge of healthcare fraud, kickback schemes, or false billing practices, consulting with an experienced whistleblower attorney can help you understand your options and potential rewards. The legal framework exists to protect and compensate those who have the courage to fight healthcare fraud.

Don’t let healthcare fraud continue unchecked. Consult with a qualified whistleblower attorney today to discuss your case and explore your options for seeking justice while protecting your rights.

Posted on

False Claims Act Whistleblowers – Counterclaims

Whistleblower protection lawyers in Beverly Hills - Helmer Friedman LLP.

See U.S. ex rel. Cooley v. ERMI, LLC, et al., C.A. No. 1:20-CV-4181-TWT, 2024 WL 815514, at *1 (N.D. Ga. Feb. 27, 2024)

A recent court ruling has allowed a medical equipment supplier to maintain counterclaims against a former employee who blew the whistle on the company for fraudulent activity. The employee claimed that the supplier provided medical equipment without a valid license. She also alleged that her employer had retaliated against her by stopping her from bringing the company into compliance and by subsequently forcing her out when she threatened to bring an False Claims Act (FCA) suit. The supplier denied these claims and filed counterclaims of its own. These counterclaims alleged that the employee breached her contract and fiduciary duties, and that she misled the company into thinking that a license renewal was forthcoming.

In February 2024, the Court made a decision to uphold the defendant’s counterclaims. The Court clarified that counterclaims for causes of action that are different from the FCA could proceed, even if they came from the same underlying facts as the FCA action. In this case, the Relator’s FCA claim and Defendant’s counterclaims both involved operating without a valid license.

The Court allowed Defendant’s breach of contract counterclaim for the time being. It reasoned that it was too early in the litigation to determine whether Relator fell within the confidentiality agreement’s safe harbor. This safe harbor allows the disclosure of confidential information to a regulator concerning conduct that an employee reasonably believes is illegal or in material noncompliance with applicable laws. If it turns out that Relator retained confidential documents only to support her FCA claim, then this counterclaim could be dismissed on public policy grounds.

The Court agreed with Defendant that Relator’s role in allowing Defendant’s Florida license to expire and misleading it into thinking a renewal was forthcoming was unrelated to the underlying FCA claims. The competitor’s lawsuit against Defendant was brought under the Florida Deceptive and Unfair Trade Practices Act, not the FCA. Therefore, that claim constituted independent damages that did not offset FCA liability.

The Court upheld Defendant’s breach of fiduciary duty claims, as they were not violative of public policy. The Court determined that there was a clear distinction between the facts supporting liability for each claim, even though both the Relator’s FCA claim and Defendant’s counterclaims involved operating without a valid license. The Court held that overlap is what makes Defendant’s counterclaims compulsory.

The court allowed the supplier’s breach of contract counterclaim to proceed for the time being, stating that it was too early in the litigation to determine whether the employee’s actions fell within the confidentiality agreement’s safe harbor provision. If it is later determined that the employee retained confidential documents only to support her fraudulent activity claim, then the counterclaim could be dismissed on public policy grounds.

This ruling provides a roadmap for companies facing fraudulent activity claims to pursue remedies against whistleblowers, even if these counterclaims stem from the same underlying facts as the fraudulent activity claim. Companies should evaluate potential injuries imposed by the whistleblower’s actions during and after their tenure, and determine whether counterclaims may be appropriate.

Posted on

Liability Under FCA Depends On Whether Defendants Believe They Lied

If you have information about violations of The False Claims Act contact an attorney for information about Whistleblower protection and rewards.

Liability Under FCA Depends On Whether Defendants Believe They Lied

United States et al. ex rel. Schutte et al. v. Supervalu Inc. et al., 2023 WL 3742577 (2023)

The False Claims Act imposes liability on anyone who “knowingly” submits a “false” claim to the Government. 31 U. S. C. §3729(a). In some cases, that rule is straightforward: If a law authorized payment of $100 for “each” medical test, and a doctor knows that he did five tests but submits a claim for ten, then he has knowingly submitted a false claim. But sometimes, the rule is less clear. If a law authorized payment for only “customary” medical tests, some doctors might be confused when it came time for billing. And, while some doctors might honestly mistake what that term means, others might correctly understand whatever “customary” meant in this context—and submit claims that were inaccurate anyway. The cases before the Supreme Court involved a legal standard similar to that latter example: In certain circumstances, pharmacies are required to bill Medicare and Medicaid for their “usual and customary” drug prices. And, critically, these cases involved defendants who may have correctly understood the relevant standard and submitted inaccurate claims anyway. The question presented is thus whether the defendants could have the scienter required by the FCA if they correctly understood that standard and thought that their claims were inaccurate.

In a unanimous decision authored by Justice Thomas, the Supreme Court held that the answer is yes: What matters for an FCA case is whether the defendant knew the claim was false. Thus, if defendants correctly interpreted the relevant phrase and believed their claims were false, then they could have known their claims were false.